The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | How may baseline cfDNA fragmentomic signatures be used as a progression risk biomarker in MM?
Dory Abelman, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the potential of using cell-free DNA (cfDNA) fragmentomic signatures in peripheral blood as biomarkers to predict measurable residual disease (MRD) status and progression risk in patients with multiple myeloma (MM). Dr Abelman highlights that while fragmentomics alone was insufficient to achieve a high correlation with bone marrow-based MRD tests, analysis of fragment length and transcription start site coverage revealed distinct signatures at diagnosis that correlated with earlier progression events and high-risk cytogenetic features. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
